Daiichi Sankyo has signed a research partnership with Interna Therapeutics to develop targeted delivery solutions based on ...

For decades, drug developers have been confronted by the stubborn reality that most of the targets inside cells remain undruggable. Estimates suggest that as many as 85% of intracellular proteins ...

Interna Therapeutics, a clinical stage biotechnology company advancing its Molecular Nano Motor (MNM) intracellular delivery platform, today announced a research collaboration with Daiichi Sankyo (TSE ...